Heiss P, Bernatz S, Bruchelt G, Senekowitsch-Schmidtke R
Nuklearmedizinische Klinik der Technischen Universität München, Germany.
Anticancer Res. 1997 Jul-Aug;17(4B):3177-8.
As a new treatment protocol for neuroblastoma, the chimeric (human/mouse) antiganglioside GD2 antibody chl4.18 is being clinically tested. To improve the therapeutic effect of the antibody alone, we are currently investigating the cytotoxicity of glucose-oxidase coupled to the antibody chl4.18 on spheroids of the neuroblastoma cell line SK-N-LO. The cytotoxic effect of glucose-oxidase is achieved by the production of hydrogenperoxide (H2O2) and probably by the following reaction of H2O2 with iron to form hydrogen radicals (OH.). The cytotoxicity of glucose-oxidase was measured by two viability tests (MTT and WST 1). After a 4 hour treatment of the spheroids with the immunoconjugate, a reduction of viability to 50% (MTT-test) and 25% (WST 1-test), respectively, was obtained. The difference between the results of these two tests, might be explained by the different measurement protocols.
作为一种用于神经母细胞瘤的新治疗方案，嵌合型（人/鼠）抗神经节苷脂GD2抗体chl4.18正在进行临床试验。为了提高单独使用该抗体的治疗效果，我们目前正在研究与抗体chl4.18偶联的葡萄糖氧化酶对神经母细胞瘤细胞系SK-N-LO球体的细胞毒性。葡萄糖氧化酶的细胞毒性是通过产生过氧化氢（H2O2）以及可能通过H2O2随后与铁反应形成氢自由基（OH.）来实现的。通过两种活力测试（MTT和WST 1）来测定葡萄糖氧化酶的细胞毒性。用免疫缀合物处理球体4小时后，活力分别降至50%（MTT测试）和25%（WST 1测试）。这两种测试结果之间的差异可能由不同的测量方案来解释。
